Please login to the form below

Not currently logged in
Email:
Password:

2seventy bio

This page shows the latest 2seventy bio news and features for those working in and with pharma, biotech and healthcare.

BMS and 2seventy bio announce positive results for multiple myeloma treatment

BMS and 2seventy bio announce positive results for multiple myeloma treatment

Bristol Myers Squibb (BMS) and 2seventy bio – a spin-out of bluebird bio – have announced positive phase 3 trial top-line results for Abecma (idecabtagene vicleucel) as a treatment for relapsed ... Steve Bernstein, chief medical officer, 2seventy bio,

Latest news

  • BMS and 2seventy bio move away from CAR-T programme BMS and 2seventy bio move away from CAR-T programme

    2021. The decision made by BMS and 2seventy bio reinforces that the companies’ hopes are pinned on Abecma, as the drug has been in high demand. ... Both companies said they anticipated between $250m and $300m in Abecma sales in 2021, with profits to be

  • bluebird bio splits to create new oncology firm 2seventy bio bluebird bio splits to create new oncology firm 2seventy bio

    2seventy bio gets the company’s immune-oncology cell therapies products, while bluebird bio will continue its work on severe genetic diseases. ... As announced earlier this year, Cambridge, Massachusetts-based bluebird bio has spun off its oncology

  • bluebird bio provides update on 2seventy bio spin-off bluebird bio provides update on 2seventy bio spin-off

    bluebird bio has announced the filing by 2seventy bio of an updated Registration Statement with the US Securities and Exchange Commission (SEC). ... This reflects bluebird bio’s plans for a spin-off of its oncology programmes and portfolio into

  • bluebird bio gears up for split bluebird bio gears up for split

    The company has filled its coffers with $75m in new funding and hired new leaders to support its split into two separate companies, bluebird bio and 2seventy bio. ... In October, the company will split into two independent, publicly traded companies,

  • Gene therapy company bluebird bio quits Europe Gene therapy company bluebird bio quits Europe

    This is not the first such incident for bluebird bio’s gene therapies. ... The company will continue its planned split into two independent, publicly traded companies – bluebird bio and 2seventy bio – by the end of 2021.

More from news
Approximately 6 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Onyx Health

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...